Private equity (PE) firms represent the strongest competitors for strategic buyers in the hospice mergers-and-acquisitions market. Hospice M&A activity cooled off across the board during the first quarter of 2022. In part, this is because a range of buyers scrambled to complete deals during late 2021 and are now focused on integrating those assets. But […]
This year was transformational for the hospice space. The industry took its first steps towards value-based payment through the hospice component of the value-based insurance design model, or Medicare Advantage hospice carve-in. Providers also saw an overhaul of the U.S. Centers for Medicare & Medicaid Services’ (CMS) survey process, all while contending with COVID-19 headwinds […]
Despite facing forceful pandemic-related headwinds from COVID-19, mergers and acquisitions and organic growth are fueling market share growth among the organizations listed in the LexisNexis 2020 Top Hospice Providers report. VITAS Healthcare, a subsidiary of Chemed Corp. (NYSE: CHE), led the charge as the largest hospice provider in the United States last year, with 4.42% […]
Amedisys, Inc. (NASDAQ:AMED) has completed its acquisition of Homecare Preferred Choice, Inc., doing business as AseraCare Hospice. Amedisys acquired 100% ownership of AseraCare for a cash price of $235 million. AseraCare operates 44 hospice locations throughout 14 states with an average daily census that exceeds 2,100. The company generates $117 million in revenue annually. With […]
The Amedisys, Inc. (NASDAQ: AMED) hospice segment saw a drop in referrals and rising costs stemming from the COVID-19 pandemic during the first quarter of this year. Though the outbreak creates industry-wide uncertainty about the future, demographic tailwinds, de novo activity and acquisitions show promise for a strong recovery, including the company’s $235 million purchase […]
Hospice and home health provider Amedisys, Inc. (NASDAQ:AMED) has entered into a definitive agreement to purchase Texas-based AseraCare Hospice for a cash purchase price of $235 million. Amedisys has had its eye on AseraCare for a number of years. “In 2016 we actually approached the AseraCare, and at that time they weren’t for sale. We’ve […]
Amedisys, Inc. (NASDAQ: AMED) has entered into a definitive agreement to purchase Asana Hospice for an undisclosed amount. The transaction is expected to close Jan. 1, 2020. Amedisys has been doubling down on hospice acquisitions this year, building up its hospice footprint as the company braces for disruption to its home health care business stemming […]
Though the hospice space remains fragmented, mergers and acquisitions are driving up market share, particularly for large providers. Along with service diversification and application of emerging technologies, M&A is helping to drive growth among the organizations named in LexisNexis Top 100 Hospices of 2019. With 4.5% of market share, VITAS Healthcare, a subsidiary of Chemed […]
Amedisys Inc. (NASDAQ: AMED) is continuing to use acquisitions to build up its hospice footprint as the company braces for disruption to its home health care business stemming from the forthcoming transition to the patient driven groupings model (PDGM). In the third quarter of 2019 Amedisys hospice segment revenue rose to $162 million, a 57% […]
All signs point to a strong showing for hospice mergers and acquisitions through the year and into 2020 as companies and investors shy away from home health in anticipation of potential fallout from the forthcoming patient-driven groupings (PDGM) model. Eight hospice acquisitions took place during the first quarter of 2019, up from seven transactions during […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
